General Healthcare

Osimertinib plus savolitinib cut death risk by 32% versus chemotherapy in selected patients with resistant lung cancer, according to new trial results presented at ESMO 2026.

Intismeran improved melanoma outcomes and reduced reoccurrence by over 40%, but leaked trial data fell short of investor expectations, hitting Moderna and Merck shares.

The AD-SMART trial will test whether diabetes drug metformin and ADHD medicine atomoxetine can slow the progression of Alzheimer’s disease in an initial 1,200 participants.

Government proposals would restrict high-risk cosmetic procedures to qualified professionals and strengthen patient protection.

The UK BioIndustry Association (BIA) has responded to the Medicines and Healthcare products Regulatory Agency (MHRA)’s 2030 Strategy, welcoming their “pro-innovation regulatory agenda.”

The UK announces plans to accelerate brain cancer research, expand clinical trials and speed up access to treatments.

The MHRA plans to align assessments with NICE to bring some new medicines to patients three to six months earlier.

MHRA outlines plans for AI oversight, medicines development and safety monitoring in its strategy to 2030.